Flush With CF Success, Vertex Prepares Next-Gen Pipeline For Busy 2023
Sickle Cell Therapy Could Be Approved Next Year
Executive Summary
Vertex’s dominance in cystic fibrosis looks secure for years to come, and 2023 and 2024 could see it bring more ground-breaking innovation to market.
You may also be interested in...
Vertex/CRISPR Are First To US FDA With A CRISPR Gene-Editing Therapy For Sickle Cell Disease
The companies completed a rolling BLA filing for exagamglogene autotemcel (exa-cel) for sickle cell disease and beta thalassemia, a decade after the discovery of CRISPR.
Vertex Readies For Commercial Future For Multi-Therapeutic Area R&D Strategy
Chief operating officer Stuart Arbuckle and chief scientific officer David Altshuler talked to Scrip about potential launches in sickle cell disease and pain, and the firm’s expanding pipeline.
Vertex Adds To Myotonic Dystrophy Effort With Entrada Collaboration
Entrada gets $250m cash and equity up front under four-year deal, which extends its runway and will enable it to focus on Duchenne muscular dystrophy. Vertex further diversifies its pipeline with a novel drug class.